AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 33 min read$MD

ORDAN MARK S sold (to issuer) 97,174 shares of MD

ORDAN MARK S (Chief Executive Officer) sold (to issuer) 97,174 shares of Pediatrix Medical Group, Inc. (MD) on 2026-06-02.

Original reporting
SEC EDGAR · ORDAN MARK S
Published Jun 3, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 9:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$MD
Neutral
medium confidence
Mentioned
$MD
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MDNeutralLow
01

Why it matters

The disclosure updates ownership records but does not provide new operating or financial fundamentals. Traders may use it as a sentiment/positioning input rather than a catalyst.

02

Market read

Ownership-change disclosure for MD; likely low incremental trading signal absent additional context (price, reason, or pattern).

03

What to watch

The transaction code is D (sale to issuer) and the price is not disclosed; without knowing whether it’s tied to a planned issuer action, the informational content is constrained.

Relevance 6/10Novelty 6/10Timing: SEC Form 4 filed after-hours (2026-06-03) for a 2026-06-02 insider sale

Background

SEC Form 4 reports insider transactions by officers/directors/10% owners; this filing shows a CEO sale to the issuer for Pediatrix Medical Group.

Company-level read

Ticker impact

$MDNeutralMedium confidence
Context

Pediatrix Medical Group CEO Ordan Mark S sold 97,174 shares via a sale to the issuer, disclosed on SEC Form 4.

Expected impact

Likely minimal near-term impact; watch for follow-on insider activity or unusual volume.

Evidence & confidence

This is an ownership-change disclosure without price/value or stated reason; Form 4 insider sales often have non-informational drivers, especially when tied to issuer actions.

Market effects

Sector

Limited read-through to the healthcare services sector; this is company-specific insider transaction data.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If the sale is not buyback-related and is discretionary, it could be interpreted as mild caution—though the filing provides no price/value or stated rationale.

Key entities

  • issuer
    Pediatrix Medical Group, Inc.

    MD; CEO Ordan Mark S reported a sale to the issuer of 97,174 shares.

  • insider
    Ordan Mark S

    CEO and officer/director; executed the reported insider transaction.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MD insider trading history →

Related articles

AUG 11
$MDMedAI 8/10

Pediatrix Medical Group (MD) Q2 2026 Earnings Call Transcript

Pediatrix Medical Group (MD) reported Q2 2026 revenue of $487.8 million, up 4% y/y, with adjusted EPS of $0.63 and adjusted EBITDA of $76.4 million. Net income was $39.8 million. Patient volume fell 2.1% y/y, while same-unit pricing rose 4%. CFO Rossi reaffirmed full-year 2026 adjusted EBITDA guidance of $280 million to $300 million.

fool.com6 min
AUG 4
$MDMed

Pediatrix Medical Group Reports Second Quarter Results

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Reports Second Quarter Results FORT LAUDERDALE, Fla., August 4, 2026 - Pediatrix Medical G

SEC EDGAR 8-K6 min
JUL 15
$MDMed

Pediatrix Medical Group Provides Second Quarter Update

Pediatrix Medical Group, Inc. (MD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 md-ex99_1.htm EX-99.1 EX-99.1 FOR MORE INFORMATION: Kasandra H. Rossi Executive Vice President, Chief Financial Officer & Treasurer 954-692-7163 kasandra.rossi@pediatrix.com FOR IMMEDIATE RELEASE Pediatrix Medical Group Provides Second Quarter Update FORT LAUDERDALE, Fl

SEC EDGAR 8-K3 min
MAY 27
$MDHighAI 9/10

Does Pediatrix Medical Group (MD) Stock Look Better After Q1 Report?

Pediatrix Medical Group (NYSE:MD) reported Q1 2026 results on May 5. Revenue rose to $476.2 million from $458.4 million a year earlier, beating the $465.7 million analyst estimate, according to the company. Adjusted EBITDA increased to $58.2 million from $49.2 million. Adjusted EPS was $0.44 vs. $0.33 a year ago, above the $0.38 estimate. The company expects full-year 2026 adjusted EBITDA of $280–$300 million.

finance.yahoo.com5 min